Elevation Point Wealth Partners LLC Purchases Shares of 6,334 Natera, Inc. $NTRA

Elevation Point Wealth Partners LLC bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 6,334 shares of the medical research company’s stock, valued at approximately $1,719,000.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Natera during the second quarter valued at $2,962,770,000. K.J. Harrison & Partners Inc acquired a new position in Natera in the 2nd quarter valued at about $5,117,000. Abbot Financial Management Inc. purchased a new position in Natera in the 2nd quarter valued at about $1,537,000. UBS Group AG lifted its holdings in Natera by 19.4% in the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after purchasing an additional 71,355 shares in the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Natera by 3,373.1% during the 1st quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company’s stock worth $2,251,000 after purchasing an additional 10,929 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ NTRA opened at $332.03 on Monday. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $333.56. The company has a market capitalization of $47.86 billion, a price-to-earnings ratio of -244.14 and a beta of 1.51. The business has a 50-day moving average of $274.24 and a 200-day moving average of $229.38.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company’s revenue was up 37.7% on a year-over-year basis. During the same period last year, the business posted ($0.74) EPS. Research analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Insider Activity

In other Natera news, insider John Fesko sold 295 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total value of $79,057.05. Following the transaction, the insider owned 183,774 shares in the company, valued at $49,249,594.26. The trade was a 0.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 181,045 shares of company stock worth $41,330,968. Company insiders own 5.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on NTRA shares. The Goldman Sachs Group started coverage on shares of Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 target price on the stock. Morgan Stanley restated an “overweight” rating and set a $355.00 price target on shares of Natera in a research note on Monday, August 10th. Stephens lifted their price target on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Guggenheim boosted their price objective on shares of Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Leerink Partners set a $330.00 price objective on shares of Natera in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.